sortiwa
[ad_1]
NEW DELHI: Even as there is still question hanging over the efficacy of hydroxychloroquine (HCQ) as medication for Covid-19, Swiss drug maker Novartis announced trials to evaluate use of HCQ for the treatment of hospitalised patients.
Novartis said that it will proceed with Phase-III clinical trials with approximately 440 patients. The clinical trial drug supply will be provided by Sandoz, the generics and biosimilars division of Novartis, it said.
“In short term, repurposing existing medicines to help treat Covid-19 is our best hope. We are working to help generate rigorous clinical testing and data needed to assess safety and efficacy of some of the most promising options as quickly as possible,” Vas Narasimhan, CEO of Novartis, tweeted . The trial will be conducted at more than a dozen sites in the US. Novartis plans to begin enrolment for this study in the next few weeks.
[ad_2]
Source link
